HI Everyone
While everything in the company seems right, the claim of the
management to grow revenue by 15% annually seems questionable as the market itself grows at 5%. The top 3-4 players have together a market share of 20% globally. Usha stands at approx 4-5% market share in international mkt and 70% in India. So a drastic increase in market share doesn’t seem to be a possibility. So will a slow revenue growth of 8-9% makes it a candidate for rerating from these levels. Also are the current valuations at right level for an entry into the stock. Would appreciate any opinion on the above issues
| Subscribe To Our Free Newsletter |
